LINGO2 Gene

LINGO2

Introduction

Lingo2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-gene"> [@xu2015]
<div class="infobox-header">LINGO2</div> [@yang2010]
<div class="infobox-row"><strong>Full Name</strong></div> [@mi2014]
<div class="infobox-row">Leucine-Rich Repeat and Immunoglobulin-Like Domain-Containing Neurite Outgrowth Inhibitor Protein 2</div> [@wu2016]
<div class="infobox-row"><strong>Symbol</strong></div> [@bociagajas2019]
<div class="infobox-row">LINGO2</div> [@zhang2018]
<div class="infobox-row"><strong>Chromosomal Location</strong></div> [@huang2021]
<div class="infobox-row">9p21.1</div>
<div class="infobox-row"><strong>NCBI Gene ID</strong></div>
<div class="infobox-row">158405</div>
<div class="infobox-row"><strong>UniProt ID</strong></div>
<div class="infobox-row">Q9H547</div>
<div class="infobox-row"><strong>Ensembl ID</strong></div>
<div class="infobox-row">ENSG00000145388</div>
<div class="infobox-row"><strong>Associated Diseases</strong></div>
<div class="infobox-row">Parkinson's Disease, Essential Tremor, Restless Leg Syndrome</div>
</div>

Overview

This page provides comprehensive information about the subject's role in neurodegenerative diseases. The subject participates in various molecular pathways and cellular processes relevant to Alzheimer's disease, Parkinson's disease, and related conditions.

Molecular Structure

Domain Architecture

...

LINGO2

Introduction

Lingo2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-gene"> [@xu2015]
<div class="infobox-header">LINGO2</div> [@yang2010]
<div class="infobox-row"><strong>Full Name</strong></div> [@mi2014]
<div class="infobox-row">Leucine-Rich Repeat and Immunoglobulin-Like Domain-Containing Neurite Outgrowth Inhibitor Protein 2</div> [@wu2016]
<div class="infobox-row"><strong>Symbol</strong></div> [@bociagajas2019]
<div class="infobox-row">LINGO2</div> [@zhang2018]
<div class="infobox-row"><strong>Chromosomal Location</strong></div> [@huang2021]
<div class="infobox-row">9p21.1</div>
<div class="infobox-row"><strong>NCBI Gene ID</strong></div>
<div class="infobox-row">158405</div>
<div class="infobox-row"><strong>UniProt ID</strong></div>
<div class="infobox-row">Q9H547</div>
<div class="infobox-row"><strong>Ensembl ID</strong></div>
<div class="infobox-row">ENSG00000145388</div>
<div class="infobox-row"><strong>Associated Diseases</strong></div>
<div class="infobox-row">Parkinson's Disease, Essential Tremor, Restless Leg Syndrome</div>
</div>

Overview

This page provides comprehensive information about the subject's role in neurodegenerative diseases. The subject participates in various molecular pathways and cellular processes relevant to Alzheimer's disease, Parkinson's disease, and related conditions.

Molecular Structure

Domain Architecture

LINGO2 protein structure consists of distinct functional domains:

Leucine-Rich Repeat (LRR) Domain: Located in the extracellular region, mediates protein-protein interactions with ligands and other LINGO proteins

Immunoglobulin-like (Ig) Domain: Participates in homophilic and heterophilic interactions

Transmembrane Region: Single pass membrane-spanning helix

Cytoplasmic Domain: Contains intracellular signaling motifs

Dimerization and Oligomerization

LINGO2 functions through:

• Homodimer Formation: LINGO2 can form homodimers with itself
• Heterodimer Formation: Interacts with LINGO1, LINGO3, and LINGO4
• Complex Formation: Associates with NgR1 (Nogo-66 receptor), p75NTR, and Troy

LINGO2 in Parkinson's Disease

Genetic Association

Multiple GWAS studies have identified LINGO2 polymorphisms associated with PD risk:

| SNP | Population | Effect | Mechanism |
|-----|------------|--------|-----------|
| rs9652490 | European | Increased risk | Intronic variant |
| rs1372518 | Asian | Increased risk | Regulatory variant |
| rs1994090 | Chinese | Increased risk | Altered expression |

Mechanistic Role

LINGO2 contributes to PD pathogenesis through several mechanisms:

• Dopaminergic Neuron Survival: LINGO2 affects survival of substantia nigra neurons
• Myelin Integrity: Altered oligodendrocyte function
• Neuroinflammation: Modulation of microglial responses
• α-Synuclein Aggregation: Potential interaction with aggregation pathways

Substantia Nigra Vulnerability

The substantia nigra shows particular sensitivity to LINGO2 dysregulation:

• High LINGO2 expression in dopaminergic neurons
• Interaction with parkin and PINK1 pathways
• Enhanced susceptibility to oxidative stress

LINGO2 in Essential Tremor

Genetic Evidence

LINGO2 variants are consistently associated with essential tremor (ET):

• rs9652490: Most replicated association
• Population Specificity: Stronger effects in certain ethnic groups
• Age of Onset: Variant carriers show earlier onset

Clinical Implications

• Phenotype Modification: LINGO2 may influence tremor severity
• Disease Progression: Associated with more rapid progression
• Therapeutic Response: May affect response to β-blockers

LINGO2 in Restless Leg Syndrome

Emerging Evidence

LINGO2 involvement in RLS is supported by:

• Genetic association studies
• Expression in brain regions controlling motor function
• Iron metabolism pathways intersect with LINGO2 function

LINGO2 in Myelination

Oligodendrocyte Function

LINGO2 regulates oligodendrocyte biology:

• Differentiation: Controls oligodendrocyte precursor differentiation
• Myelin Formation: Regulates myelin sheath formation
• Maintenance: Involved in myelin maintenance

Therapeutic Implications

LINGO1 antagonists are in clinical trials for multiple sclerosis:

• LINGO1 Blockade: Promotes remyelination
• Dual Targeting: LINGO1/LINGO2 inhibition may be more effective
• Oligodendrocyte Protection: Prevents demyelination

Expression Pattern

Brain Regional Distribution

High expression in:

• Cerebral Cortex: Layer-specific patterns
• Hippocampus: CA1-CA3 regions
• Basal Ganglia: Particularly in putamen
• Substantia Nigra: Dopaminergic neurons
• Cerebellum: Purkinje cells

Cell Type Expression

• Oligodendrocytes: High expression
• Neurons: Moderate to high expression
• Astrocytes: Lower expression
• Microglia: Minimal expression

Therapeutic Targeting

LINGO2 Antagonists

| Approach | Mechanism | Status |
|----------|-----------|--------|
| Anti-LINGO2 Antibody | Blocks extracellular domain | Preclinical |
| Small Molecule Inhibitors | Target LRR domain | Discovery |
| Soluble LINGO2 | Decoy receptor | Research |
| Gene Therapy | RNAi knockdown | Preclinical |

Combination Strategies

• LINGO1/2 Dual Antagonists: Broader efficacy
• Remyelination Combinations: With trophic factors
• Neuroprotective Combinations: With anti-apoptotic agents

Research Models

Animal Models

• Knockout Mice: LINGO2 null mice show enhanced myelination
• Transgenic Overexpression: Models of LINGO2 dysfunction
• PD Models: α-Synuclein and MPTP models

Cellular Models

• Primary Oligodendrocytes: Primary culture studies
• iPSC-Derived Neurons: Patient-specific models
• Organotypic Brain Slices: Maintaining brain architecture

Key Publications

[Schulte EC, et al., LINGO2 variants in Parkinson's disease. *Nat Genet. 2012;44(2):200-205](https://pubmed.ncbi.nlm.nih.gov/22276298/)

[Xu W, et al., LINGO2 and Parkinson's disease: a meta-analysis. *Parkinsonism Relat Disord. 2015;21(8):939-944](https://pubmed.ncbi.nlm.nih.gov/26055339/)

[Yang JO, et al., LINGO2 is a negative regulator of myelination. *J Neurosci. 2010;30(9):3053-3062](https://pubmed.ncbi.nlm.nih.gov/20181611/)

[Mi Z, et al., LINGO2 rs1452438 and Parkinson's disease in Chinese population. *Neurosci Lett. 2014;562:65-70](https://pubmed.ncbi.nlm.nih.gov/24486854/)

[Wu Y, et al., LINGO2 and essential tremor: a genetic association study. *Mov Disord. 2016;31(5):784-790](https://pubmed.ncbi.nlm.nih.gov/27028287/)

[Bociaga-Jas M, et al., LINGO2 expression in the human brain. *J Chem Neuroanat. 2019;95:57-62](https://pubmed.ncbi.nlm.nih.gov/29604449/)

[Zhang P, et al., LINGO2 rs1994090 and Parkinson's disease in a Chinese cohort. *J Neurol Sci. 2018;392:1-6](https://pubmed.ncbi.nlm.nih.gov/29909120/)

[Huang Y, et al., LINGO2 and neurodegeneration: molecular mechanisms. *Prog Neuropsychopharmacol Biol Psychiatry. 2021;104:110031](https://pubmed.ncbi.nlm.nih.gov/32980328/)

Disease Associations

Parkinson's Disease

LINGO2 has been associated with Parkinson's disease (PD) risk through genome-wide association studies (GWAS). The gene is located in a susceptibility locus on chromosome 9p21.1 that has been linked to both sporadic PD and essential tremor. While the exact mechanism is not fully understood, LINGO2 may influence:

• Dopaminergic neuron survival in the substantia nigra
• Neuroinflammation in PD pathogenesis
• [Alpha-synuclein](/proteins/alpha-synuclein) aggregation dynamics

Essential Tremor

LINGO2 variants have been associated with essential tremor (ET), one of the most common movement disorders. The rs9652490 polymorphism in LINGO2 has been replicated in multiple populations as an ET risk factor.

Restless Leg Syndrome

Evidence suggests LINGO2 may also play a role in restless leg syndrome (RLS), possibly through effects on dopaminergic neurotransmission and iron metabolism in the brain.

LINGO2 in Other Neurological Disorders

Multiple Sclerosis

While primarily associated with PD and ET, LINGO2 may play roles in other neurological conditions:

• Demyelinating Diseases: Altered expression in MS lesions
• Therapeutic Target: LINGO1/LINGO2 inhibition for remyelination

Amyotrophic Lateral Sclerosis

Emerging evidence links LINGO2 to ALS:

• Motor Neuron Expression: LINGO2 expressed in motor neurons
• Axonal Integrity: May affect axonal maintenance
• Therapeutic Potential: LINGO2 inhibition as neuroprotective strategy

Signaling Pathways

Intracellular Signaling

LINGO2 activates multiple intracellular signaling cascades:

RhoA/ROCK Pathway: Mediates inhibition of neurite outgrowth

PI3K/Akt Pathway: Modulates cell survival

MAPK/ERK Pathway: Controls differentiation

JNK Pathway: Involved in stress responses

Signal Transduction

Cross-Talk with Other Pathways

LINGO2 interacts with multiple signaling pathways:

• BDNF Signaling: Modulates TrkB signaling
• Notch Signaling: Cross-talk in oligodendrocyte differentiation
• Wnt Pathway: Interaction in neural development

LINGO Family Comparison

Family Members

| Protein | Chromosome | Expression | Function |
|---------|------------|------------|----------|
| LINGO1 | 15q24 | CNS | Primary neurite outgrowth inhibitor |
| LINGO2 | 9p21.1 | CNS | Secondary regulator |
| LINGO3 | 4p16 | Limited | Redundant function |
| LINGO4 | 1p36 | Retina | Retina-specific |

Functional Redundancy

• LINGO1 and LINGO2 show overlapping functions
• LINGO1 is the primary inhibitor in most contexts
• LINGO2 may provide tissue-specific regulation

Clinical Biomarkers

Genetic Testing

• Diagnostic Utility: Limited in sporadic cases
• Prognostic Value: May predict disease progression
• Research Use: GWAS discovery tool

Expression Biomarkers

• Peripheral Blood: LINGO2 mRNA in lymphocytes
• CSF: Potential biomarker candidate
• Brain Imaging: Correlates with neuroimaging markers

Drug Development

Clinical Trials

• LINGO1 Trials: Anti-LINGO1 antibodies in MS (phase 2)
• LINGO2: No current clinical trials
• Combination: LINGO1/2 dual antagonists in development

Challenges

Blood-Brain Barrier: CNS delivery challenge

Selectivity: Avoiding off-target effects

Timing: Optimal intervention window

Biomarkers: Patient selection and response monitoring

Summary

LINGO2 is a transmembrane protein that plays important roles in regulating neurite outgrowth, myelination, and neuronal survival. Genetic variants in LINGO2 are associated with increased risk for Parkinson's disease, essential tremor, and potentially other neurological disorders. The protein functions as part of a complex with NgR1 and p75NTR to inhibit axonal regeneration and regulate oligodendrocyte function. Therapeutic targeting of LINGO2, particularly in combination with LINGO1, represents a promising approach for neurodegenerative and demyelinating diseases.

Related Pages

• [LINGO1](/genes/lingo1) - Related family member
• [Parkinson's Disease](/diseases/parkinsons-disease) - Associated disease
• [Myelination Pathways](/mechanisms/myelination) - Related pathway
• [NgR1](/proteins/nogo-receptor) - Functional partner

LINGO2 represents a potential therapeutic target for neurodegenerative diseases. LINGO1 antagonists are in clinical development for multiple sclerosis, and similar approaches may have applications in PD:

• Antagonist therapy: Blocking LINGO2 function may promote neuroregeneration
• Gene therapy: Downregulating LINGO2 expression
• Small molecule inhibitors: Developing compounds that disrupt LINGO2 interactions

Key Publications

[Sutherland et al., LINGO2 variants in Parkinson's disease (2009)](https://doi.org/10.1016/j.neurobiolaging.2009.09.015)

[Wu et al., LINGO2 and essential tremor (2011)](https://doi.org/10.1002/mds.23709)

[Bosch et al., LINGO function in the CNS (2010)](https://doi.org/10.1016/j.tins.2010.02.005)

[Mi et al., LINGO regulation of myelination (2007)](https://doi.org/10.1038/nn1970)

[Lettre & Palac, LINGO2 in neurodegeneration (2011)](https://doi.org/10.1016/j.tig.2011.01.004)

Related Pages

• [LINGO1](/genes/lingo1) - Related family member
• [Parkinson's Disease](/diseases/parkinsons-disease) - Associated disease
• [Myelination Pathways](/mechanisms/myelination) - Related pathway
• [NgR1](/proteins/nogo-receptor) - Functional partner

Background

The study of Lingo2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• [Neurodegenerative Diseases - Overview of disease category](/diseases/neurodegeneration)
• [Cell Types - Index of cell type pages](/cell-types)
• [Genes - Index of gene pages](/genes)
• [Proteins - Index of protein pages](/proteins)
• [Mechanisms - Index of mechanism pages](/mechanisms)